PLSE SEC-Einreichungen - Pulse Biosciences, Inc.- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

LEI	529900NJUBI06118FM73
CIK	1625101

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Pulse Biosciences, Inc.

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 14, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-34899 Pulse Bio
May 11, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State
May 6, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 5, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 4, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 4, 2026	EX-99.1	Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results Exhibit 99.1 Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results Accelerates Enrollment Timeline for the Cardiac Catheter IDE Conference Call to Be Held Thursday, May 7th to Discuss Business Updates and Financial Results HAYWARD, California [Business Wire] – May 4, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary
April 30, 2026	EX-19.1	INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective March 11, 2026 Exhibit 19.1 INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective March 11, 2026 Federal and state securities laws prohibit any person who is aware of material nonpublic information about a company from trading in securities of that company. These laws also prohibit a person from disclosing material nonpublic information to other persons who may trade on the basis of
April 30, 2026	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Bioscie
April 27, 2026	EX-99.2	EXHIBIT 99.2 Exhibit 99.2
April 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 25, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
April 27, 2026	EX-99.1	Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026 Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for ca Exhibit 99.1 Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026 Multicenter results show sustained high durability and procedural efficiency, redefining positive expectations for catheter ablation in patients with atrial fibrillation HAYWARD, California, April 25, 2026 [Business Wire] – Pulse Biosciences, Inc. (Nasda
April 16, 2026	EX-99.1	EXHIBIT 99.1 Exhibit 99.1
April 16, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 16, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 16, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
April 9, 2026	EX-99.1	Pulse Biosciences Strengthens Executive Leadership Team Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg’s Chief Medical Officer Role Exhibit 99.1 Pulse Biosciences Strengthens Executive Leadership Team Appoints Liane Teplitsky as Chief Operating Officer Expands Dr. David Kenigsberg’s Chief Medical Officer Role HAYWARD, California, April 9, 2026 – Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the strengthening of its exe
April 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 8, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
April 9, 2026	EX-10.1	PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT Exhibit 10.1 PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Liane R. Teplitsky (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of April 8, 2026. 1. Duties and Scope of Employment. (a) Position and Duties. As of April 8, 2026 (the “Start Date”), Executive will serve as the Company’s Chief Operating Offic
April 7, 2026	EX-99.1	Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibil Exhibit 99.1 Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study HAYWARD, California, April 7, 2026 – Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary
April 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): April 7, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
March 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 23, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 23, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
March 17, 2026	EX-99.1	Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data Exhibit 99.1 Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data HAYWARD, California [Business Wire] — March 17, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize
March 17, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 17, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 17, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
March 12, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 12, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
March 12, 2026	EX-99.1	Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse Exhibit 99.1 Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology HAYWARD, California. [Business Wire]– March 12, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced f
March 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 6, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
March 9, 2026	EX-99.1	Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation Exhibit 99.1 Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. HAYWARD, California, [Business Wire] – March 9, 2026, Pulse Biosciences, Inc. (Nasdaq: PLSE)
March 3, 2026	EX-99.1	EXHIBIT 99.1 - INVESTOR PRESENTATION MARCH 2026 Exhibit 99.1 - Investor Presentation March 2026
March 3, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 3, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 3, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
March 2, 2026	8-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commis
February 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 27, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
February 25, 2026	LETTER	LETTER February 25, 2026 Paul LaViolette Chief Executive Officer Pulse Biosciences, Inc. 601 Brickell Key Drive, Suite 1080 Miami, FL 33131 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 Filed February 19, 2026 File No. 333-293596 Dear Paul LaViolette: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regardi
February 25, 2026	CORRESP	PULSE BIOSCIENCES, INC. 601 Brickell Key Drive, Suite 1080 Miami, Florida 33131 (510) 906-4600 PULSE BIOSCIENCES, INC. 601 Brickell Key Drive, Suite 1080 Miami, Florida 33131 (510) 906-4600 February 25, 2026 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-293596 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under
February 19, 2026	EX-99.1	PULSE BIOSCIENCES, INC. Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results HAYWARD, California. [Business Wire] – February 19, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the
February 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 19, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 19, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
February 19, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 ☐ TRANSITION REPORT PURSUA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348
February 19, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 PULSE BIOSCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Ini
February 19, 2026	EX-4.2	PULSE BIOSCIENCES, INC. Dated as of , 20 As Trustee TABLE OF CONTENTS Exhibit 4.2 PULSE BIOSCIENCES, INC. INDENTURE Dated as of , 20 [], As Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 6 1.1 Definitions 6 1.2 Other Definitions 8 1.3 Incorporation by Reference of Trust Indenture Act 8 1.4 Rules of Construction 9 ARTICLE II THE SECURITIES 9 2.1 Issuable in Series 9 2.2 Establishment of Terms of Series of Securities 9 2.3 Executio
February 19, 2026	EX-19.1	INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective February 19, 2026 Exhibit 19.1 INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective February 19, 2026 Federal and state securities laws prohibit any person who is aware of material nonpublic information about a company from trading in securities of that company. These laws also prohibit a person from disclosing material nonpublic information to other persons who may trade on the basis
February 19, 2026	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of Incorporation Ownership Position NanoBlate Corp., a Delaware Corporation Delaware 100% BioElectroMed Corp., a California Corporation California 100% Pulse Biosciences BV Netherlands 100% 2783162 Ontario Inc. Ontario 100%
February 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 18, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 18, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
February 19, 2026	S-3	As filed with the Securities and Exchange Commission on February 19, 2026 As filed with the Securities and Exchange Commission on February 19, 2026 Registration No.
February 19, 2026	EX-FILING FEES	Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 PULSE BIOSCIENCES, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value 0.001 per share Other 3,200,000 $ 23.57 $ 75,424,000.00 0.0001381 $ 10,416.05 2 Equit
February 19, 2026	EX-14.1	CODE OF BUSINESS CONDUCT AND ETHICS Exhibit 14.1 CODE OF BUSINESS CONDUCT AND ETHICS Introduction Pulse Biosciences, Inc. (“Pulse Biosciences”) is committed to maintaining the highest standards of business conduct and ethics. This Code of Business Conduct and Ethics (“Code”) reflects the business practices and principles of behavior that support this commitment, and is designed to deter wrongdoing and promote the standards set forth
February 19, 2026	EX-10.6	PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN Exhibit 10.6 Approved by Stockholders 9/30/25 PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are: ● to attract and retain the best available personnel for positions of substantial responsibility, ● to provide additional incentive to Employees, Directors and Consultants, and ● to promote the success of the Company’s busines
February 19, 2026	EX-1.1	PULSE BIOSCIENCES, INC. Common Stock ($0.001 par value per share) EQUITY DISTRIBUTION AGREEMENT Exhibit 1.1 PULSE BIOSCIENCES, INC. Common Stock ($0.001 par value per share) EQUITY DISTRIBUTION AGREEMENT February 19, 2026 TD SECURITIES (USA) LLC 1 Vanderbilt Avenue, 11th Floor New York, New York 10017 Ladies and Gentlemen: Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time to or thr
February 19, 2026	424B5	$59,976,196 Pulse Biosciences, Inc. Common Stock Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-278322 and 333-280805 PROSPECTUS SUPPLEMENT (To Prospectus dated April 8, 2024) $59,976,196 Pulse Biosciences, Inc. Common Stock We have entered into a sales agreement (the “Sales Agreement”) with TD Securities (USA) LLC (“TD Cowen”) relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. I
February 19, 2026	S-8	As filed with the Securities and Exchange Commission on February 19, 2026 As filed with the Securities and Exchange Commission on February 19, 2026 Registration No.
February 6, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 5, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
February 6, 2026	EX-99.1	Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months Exhibit 99.1 Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium Procedural success was achieved in 100% of evaluable patients at 6 months and 96% in 12 months HAYWARD, California, February 5, 2026 [Business Wire] – Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary
January 14, 2026	EX-99.1	EXHIBIT 99.1 - INVESTOR DECK Exhibit 99.1
January 14, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
January 9, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2026 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 8, 2026 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
January 9, 2026	EX-99.1	Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors Exhibit 99.1 Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors HAYWARD, California [Business Wire] January 9, 2026 - Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effectiv
December 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 18, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
December 18, 2025	EX-99.1	Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation Exhibit 99.1 Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation HAYWARD, Calif. [Business Wire]–December 18, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today a
December 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
December 9, 2025	EX-99.1	Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse Exhibit 99.1 Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology HAYWARD, Calif. [Business Wire]–December 9, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (
December 9, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 9, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
November 13, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
November 13, 2025	EX-99.1	EXHIBIT 99.1 - INVESTOR PRESENTATION NOVEMBER 2025 Exhibit 99.1
November 5, 2025	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results HAYWARD, California. [Business Wire] – November 5, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the th
November 5, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
November 5, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 5, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
October 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State
October 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive Proxy State
October 24, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 24, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
October 24, 2025	EX-99.1	Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study Exhibit 99.1 Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study First U.S. Surgical Treatments with PFA Clamp for Patients with Atrial Fibrillation During Concomitant Surgical Procedure HAYWARD, Calif. [Business Wire]–October 24, 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™
October 10, 2025	EX-99.1	Pulse Biosciences Announces Presentation of Late-Breaking Data from the nPulse Exhibit 99.1 Pulse Biosciences Announces Presentation of Late-Breaking Data from the nPulse™ Cardiac Surgical System First-In-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting Successfully treated atrial fibrillation (AF) in initial 30 patients with the nPulse™ Cardiac Surgical System HAYWARD, Calif. [Business Wire]–October 10, 2025 Pulse Bioscienc
October 10, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 10, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
October 1, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 30, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commiss
September 18, 2025	144	144 144 0001913245 XXXXXXXX LIVE 0001625101 PULSE BIOSCIENCES INC 001-37744 601 Brickell Key Drive, Suite 1080 Miami FL 33131 510-906-4600 KEVIN DANAHY Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 25000 406750.
September 11, 2025	144	144 144 0001276311 XXXXXXXX LIVE 0001625101 PULSE BIOSCIENCES INC 001-37744 601 Brickell Key Drive, Suite 1080 Miami FL 33131 510-906-4600 DARRIN UECKER Director Officer Common Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004 120000 1772400.
September 8, 2025	EX-99.1	Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation Exhibit 99.1 Pulse Biosciences Announces FDA IDE Approval to Initiate its nsPFA Cardiac Surgery System Study for the Treatment of Atrial Fibrillation HAYWARD, Calif. [Business Wire]–September 8, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, t
September 8, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 8, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
September 3, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive
September 2, 2025	EX-99.1	Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study Exhibit 99.1 Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study HAYWARD, Calif. [Business Wire]– September 2, 2025, Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-appro
September 2, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 2, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
August 26, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 26, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
August 26, 2025	EX-99.1	Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Exhibit 99.1 Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid First-in-Human Clinical Feasibility Study Demonstrates Effectiveness of Ablation of Benign Thyroid Nodules Using Nanosecond Pulsed Field Ablation HAYWARD, Calif.-(BUSINESS WIRE) August 26, 2025- Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its n
August 18, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Definitive
August 12, 2025	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results HAYWARD, California. [Business Wire] – August 12, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the second quarter ended Ju
August 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
August 12, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
July 14, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 14, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
May 30, 2025	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc.
May 30, 2025	EX-1.01	Conflict Minerals Report of Pulse Biosciences, Inc. as required by Items 1.01 and 1.02 of this Form SD for the period January 1 - December 31, 2024. Exhibit 1.01 Conflict Minerals Report of Pulse Biosciences, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pulse Biosciences, Inc. (“Pulse Biosciences” or the “Company”) for the reporting period January 1, 2024 to December 31, 2024 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934,
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 8, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 8, 2025	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results HAYWARD, California. [Business Wire] – May 8, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31
April 30, 2025	EX-19.1	INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective May 11, 2022 Exhibit 19.1 INSIDER TRADING POLICY As Amended and Approved by the Board of Directors Effective May 11, 2022 INTRODUCTION Federal and state securities laws prohibit any person who is aware of material nonpublic information about a company from trading in securities of that company. These laws also prohibit a person from disclosing material nonpublic information to other persons who may trade on th
April 30, 2025	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K/A (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 Pulse Bioscie
April 30, 2025	EX-10.27	December 5, 2024 Exhibit 10.27 December 5, 2024 VIA HAND DELIVERY Burke Barrett Dear Burke: The purpose of this letter is to inform you that Pulse Biosciences, Inc. (the “Company”) is accepting your resignation and consequently terminating your employment effective Friday, December 6, 2024 (your “Separation Date”). On your Separation Date, you will receive your final paycheck, which will include payment for all of
March 31, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of Incorporation Ownership Position NanoBlate Corp., a Delaware Corporation Delaware 100% BioElectroMed Corp., a California Corporation California 100% Pulse Biosciences BV Netherlands 100% 2783162 Ontario Inc. Ontario 100%
March 31, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348
March 28, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
March 28, 2025	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results MIAMI, Florida. [Business Wire] – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31
February 27, 2025	EX-4.4	PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY INCENTIVE PLAN Exhibit 4.4 PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits
February 27, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc.
February 27, 2025	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Pulse Biosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 601 Brickell Key Drive, Suite 1080 Mi
February 27, 2025	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Pulse Biosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 601 Brickell Key Drive, Suite 1080 Mi
February 27, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc.
February 4, 2025	EX-99.1	Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform Exhibit 99.1 Pulse Biosciences, Inc. Appoints Jon Skinner as Chief Financial Officer Expanded executive team to support operational excellence and commercialization of the CellFX nanosecond PFA Platform MIAMI, Florida, February 4, 2025 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (n
February 4, 2025	EX-10.1	Employment Agreement Exhibit 10.1 PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Jon Skinner (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of January 31, 2025. 1. Duties and Scope of Employment. (a) Position and Duties. As of February 3, 2025 (the “Start Date”), Executive will serve as the Company’s Chief Financial Office
February 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 31, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
January 23, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 21, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 21, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
January 23, 2025	EX-99.1	Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360 Exhibit 99.1 Pulse Biosciences Announces Late-Breaking Data from its Nanosecond PFA 360° Cardiac Catheter System First-In-Human Feasibility Study Presented at the AF Symposium Successfully treated atrial fibrillation (AF) in initial 30 patients with the Nanosecond PFA 360° Cardiac Catheter MIAMI, Florida. [Business Wire]– January 21, 2025. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveragi
January 14, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2025 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 14, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
January 14, 2025	EX-99.1	Investor Deck, dated January 2025 Exhibit 99.1
January 13, 2025	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2025 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
January 13, 2025	EX-99.1	Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer Current Co-Chairman of the Board will now also serve as Chief Executive Officer Exhibit 99.1 Pulse Biosciences, Inc. Appoints Paul LaViolette as Chief Executive Officer Current Co-Chairman of the Board will now also serve as Chief Executive Officer MIAMI, Florida, January 10, 2025 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, tod
January 13, 2025	EX-10.1	Employment Agreement Exhibit 10.1 PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Paul LaViolette (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of January 9, 2025. 1. Duties and Scope of Employment. (a) Position and Duties. As of January 9, 2025 (the “Start Date”), Executive will serve as the Company’s President and Chief
December 26, 2024	EX-99.1	PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS Exhibit 99.1 PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS HAYWARD, Calif. — (BUSINESS WIRE) — December 23, 2024 — Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced that it intends to deliver an irrevocable notice of redemption, on or about December 27, 2024, t
December 26, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 23, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
December 6, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 2, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
November 26, 2024	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 26, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
October 31, 2024	EX-99.1	Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association Exhibit 99.1 Pulse Biosciences Announces Positive Clinical Data Presented at the American Thyroid Association European feasibility study demonstrates using nano-PFA in benign thyroid nodules reduces nodule volume by greater than 50% and provides symptomatic relief within the first month of treatment MIAMI, Florida. [Business Wire] – October 31, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a compa
October 31, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 31, 2024 Pulse Biosciences, Inc.
October 30, 2024	EX-99.2	Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology Exhibit 99.2 Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D. MIAMI, Florida. [Business Wire] – October 30, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Fiel
October 30, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): October 30, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissio
October 30, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
October 30, 2024	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2024 Financial Results MIAMI, Florida. [Business Wire] – October 30, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nsPFA or nano-PFA) technology, today announced business updates and financial results for
August 19, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
August 15, 2024	NT 10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-37744 CUSIP Number: 74587B101 (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: June 30, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the Transition Period Ended: Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
August 12, 2024	EX-99.1	Investor Deck, dated August 2024 EX-99.1 2 ex712662.htm INVESTOR DECK, DATED AUGUST 2024 Exhibit 99.1
August 12, 2024	EX-99.2	Pulse Biosciences, Inc. Appoints Paul LaViolette to its Board of Directors Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise Exhibit 99.2 Pulse Biosciences, Inc. Appoints Paul LaViolette to its Board of Directors Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise MIAMI, Florida, August 12, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietar
August 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 12, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
August 12, 2024	EX-99.1	Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results Exhibit 99.1 Pulse Biosciences Reports Business Updates and Preliminary Second Quarter 2024 Financial Results HAYWARD, Calif. [Business Wire] – August 12, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA) technology, today announced business updates and preliminary financi
August 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 9, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
August 8, 2024	EX-99.1	Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System Company’s proprietary system used in study for patients with atrial fibrillation Cardiac Surgery System enrolled in th Exhibit 99.1 Pulse Biosciences, Inc. Announces Successful Treatment of Patients in First-in-Human Study with its Nano-PFA Cardiac Surgery System Company’s proprietary system used in study for patients with atrial fibrillation Cardiac Surgery System enrolled in the FDA’s Total Product Life Cycle (TPLC) Advisory Program (TAP)* MIAMI, Florida, August 8, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (
August 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024 Pulse Biosciences, In UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) August 8, 2024 Pulse Biosciences, Inc.
July 15, 2024	EX-1.1	At-the-Market Equity Offering Sales Agreement Exhibit 1.1 PULSE BIOSCIENCES, INC. Common Stock ($0.001 par value per share) EQUITY DISTRIBUTION AGREEMENT July 15, 2024 CANACCORD GENUITY LLC 1 Post Office Square Suite 3000 Boston, Massachusetts 02109 NEEDHAM & COMPANY, LLC 250 Park Avenue New York, New York 10177 Ladies and Gentlemen: Pulse Biosciences, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions
July 15, 2024	424B5	Up to $60,000,000 Pulse Biosciences, Inc. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-278322 and 333-280805 PROSPECTUS SUPPLEMENT (To Prospectus dated April 8, 2024) Up to $60,000,000 Pulse Biosciences, Inc. Common Stock We have entered into an equity distribution agreement (the “Equity Distribution Agreement”) with Canaccord Genuity LLC and Needham & Company, LLC (jointly and severally, the “Agents”), r
July 15, 2024	8-K	Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 15, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
July 15, 2024	S-3MEF	As filed with the Securities and Exchange Commission on July 15, 2024 S-3MEF As filed with the Securities and Exchange Commission on July 15, 2024 Registration No.
July 15, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc.
July 8, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 8, 2024 Pulse Biosciences, Inc.
July 8, 2024	SC 13D/A	PLSE / Pulse Biosciences, Inc. / DUGGAN ROBERT W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 15)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI
July 8, 2024	EX-99.1	Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation Provides expanded access to FDA and prioritized review of submission Exhibit 99.1 Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation Provides expanded access to FDA and prioritized review of submission MIAMI, Florida, July 8, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietar
July 3, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 3, 2024 Pulse Biosciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) July 3, 2024 Pulse Biosciences, Inc.
July 3, 2024	EX-99.1	Pulse Biosciences, Inc. Announces the Closing of its Rights Offering Exhibit 99.1 Pulse Biosciences, Inc. Announces the Closing of its Rights Offering HAYWARD, Calif., July 3, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, announced today the closing of its rights offering and the final results thereof. The Company rec
June 28, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 28, 2024 Pulse Biosciences, Inc.
June 28, 2024	EX-99.1	Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering Oversubscribed offering expected to generate $60 million in immediate gross proceeds for the Company Warrants issued in the offering could generate up to an additional $66M Exhibit 99.1 Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering Oversubscribed offering expected to generate $60 million in immediate gross proceeds for the Company Warrants issued in the offering could generate up to an additional $66MM HAYWARD, Calif., June 28, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging it
June 7, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): June 6, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi
June 4, 2024	EX-99.1	Pulse Biosciences, Inc. Announces Commencement of Rights Offering Exhibit 99.1 Pulse Biosciences, Inc. Announces Commencement of Rights Offering HAYWARD, Calif., June 4, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that it has commenced its previously announced rights offering of up to $60,000,000
June 4, 2024	424B2	Pulse Biosciences, Inc. Subscription Rights to Purchase Up to 6,000,000 Units at the Initial Price Each Unit Consisting of One Share of Common Stock and Two Warrants, Each Being a Warrant to Purchase One-Half of One Share of Common Stock (and Up to 6 Filed Pursuant to Rule 424(b)(2) Registration Statement No. 333-278494 PROSPECTUS Pulse Biosciences, Inc. Subscription Rights to Purchase Up to 6,000,000 Units at the Initial Price Each Unit Consisting of One Share of Common Stock and Two Warrants, Each Being a Warrant to Purchase One-Half of One Share of Common Stock (and Up to 6,000,000 Shares of Common Stock Underlying the Warrants at 110% of t
June 4, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2024 Pulse Biosciences, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 4, 2024 Pulse Biosciences, Inc.
May 31, 2024	EX-1.01	Conflict Minerals Report of Pulse Biosciences, Inc. as required by Items 1.01 and 1.02 of this Form SD for the period January 1 - December 31, 2023. Exhibit 1.01 Conflict Minerals Report of Pulse Biosciences, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pulse Biosciences, Inc. (“Pulse Biosciences” or the “Company”) for the reporting period January 1, 2023 to December 31, 2023 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934,
May 31, 2024	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc.
May 28, 2024	POS AM	As filed with the Securities and Exchange Commission on May 28, 2024 As filed with the Securities and Exchange Commission on May 28, 2024 Registration No.
May 20, 2024	EX-99.1	Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 Exhibit 99.1 Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000 HAYWARD, Calif. – (BUSINESS WIRE) – May 20, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has determined a new
May 20, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 20, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi
May 15, 2024	EX-10.1	Employment Agreement Exhibit 10.1 PULSE BIOSCIENCES, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into by and between Burke T. Barrett (“Executive”) and Pulse Biosciences, Inc. (the “Company”), as of May 12, 2024. Certain capitalized terms used herein shall have the meanings assigned to them in Section 10 of this Agreement. 1. Duties and Scope of Employment. (a) Position an
May 15, 2024	EX-10.3	Form of Stock Option Grant Notice and Stock Option Agreement under 2017 Inducement Equity Incentive Plan Exhibit 10.3 PULSE BIOSCIENCES, INC. 2017 INDUCEMENT EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT NOTICE OF STOCK OPTION GRANT Unless otherwise defined herein, the terms defined in the Pulse Biosciences, Inc. Amended and Restated 2017 Inducement Equity Incentive Plan (the “Plan” of the “2017 Inducement Equity Incentive Plan”)) will have the same defined meanings in this Stock Option Agreement incl
May 15, 2024	EX-99.1	Pulse Biosciences Enhances Executive Leadership Team Appoints proven atrial fibrillation medical technology leader Burke T. Barrett as President and Chief Executive Officer Former President and Chief Executive Officer Kevin Danahy appointed as Chief Exhibit 99.1 Pulse Biosciences Enhances Executive Leadership Team Appoints proven atrial fibrillation medical technology leader Burke T. Barrett as President and Chief Executive Officer Former President and Chief Executive Officer Kevin Danahy appointed as Chief Commercial Officer HAYWARD, Calif. [Business Wire] – May 14, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its nove
May 15, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 12, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi
May 15, 2024	EX-10.5	Fifth Amendment to Employment Agreement, dated May 12, 2024, by and between Pulse Biosciences, Inc. and Darrin Uecker Exhibit 10.5 PULSE BIOSCIENCES, INC. FIFTH AMENDMENT TO EMPLOYMENT AGREEMENT This fifth amendment (this “Amendment”) is entered into effective as of May 12, 2024, by and between Darrin Uecker (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Company and Executive entered into an employment agreement dated September 8, 2015 (as amend
May 15, 2024	EX-10.2	Pulse Biosciences, 2017 Inducement Equity Incentive Plan Exhibit 10.2 PULSE BIOSCIENCES, INC. AMENDED AND RESTATED 2017 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals’ entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits
May 15, 2024	EX-10.4	Fourth Amendment to Employment Agreement, dated May 12, 2024, by and between Pulse Biosciences, Inc. and Kevin Danahy Exhibit 10.4 PULSE BIOSCIENCES, INC. FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This fourth amendment (this “Amendment”) is entered into effective as of May 12, 2024, by and between Kevin Danahy (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Parties entered into an employment agreement dated February 9, 2022 (as previously amended,
May 9, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 9, 2024	EX-99.1	Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System Exhibit 99.1 Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System HAYWARD, Calif. [Business Wire] – May 9, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced the first procedure with the CellFX nsPFA Percutaneous Electrode System i
May 7, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 7, 2024	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results HAYWARD, Calif. [Business Wire] – May 7, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2024. Recent
May 7, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 2, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 2, 2024	EX-99.1	Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 Exhibit 99.1 Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000 HAYWARD, Calif. – (BUSINESS WIRE) – May 2, 2024 - Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse” or the “Company”), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has set the record date for th
May 1, 2024	CORRESP	PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 May 1, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-278494 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities
April 30, 2024	CORRESP	April 30, 2024 April 30, 2024 VIA EDGAR Division of Corporation Finance United States Securities and Exchange Commission 100 F Street, N.
April 30, 2024	S-3/A	As filed with the Securities and Exchange Commission on April 30, 2024 As filed with the Securities and Exchange Commission on April 30, 2024 Registration No.
April 25, 2024	CORRESP	April 25, 2024 April 25, 2024 VIA EDGAR Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N.
April 25, 2024	S-3/A	As filed with the Securities and Exchange Commission on April 25, 2024 As filed with the Securities and Exchange Commission on April 25, 2024 Registration No.
April 24, 2024	LETTER	LETTER United States securities and exchange commission logo April 24, 2024 Kevin Danahy Chief Executive Officer Pulse Biosciences, Inc.
April 23, 2024	S-3/A	As filed with the Securities and Exchange Commission on April 23, 2024 As filed with the Securities and Exchange Commission on April 23, 2024 Registration No.
April 23, 2024	CORRESP	April 23, 2024 April 23, 2024 VIA EDGAR Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N.
April 23, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☒ Definitive Proxy State
April 23, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 DEFA14A 1 plse20240418defa14a.htm FORM DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitte
April 18, 2024	LETTER	LETTER United States securities and exchange commission logo April 18, 2024 Kevin Danahy Chief Executive Officer Pulse Biosciences, Inc.
April 15, 2024	CORRESP	April 15, 2024 April 15, 2024 Office of Industrial Applications and Services Division of Corporate Finance Securities and Exchange Commission 100 F Street, N.
April 15, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc.
April 15, 2024	S-3/A	As filed with the Securities and Exchange Commission on April 15, 2024 As filed with the Securities and Exchange Commission on April 15, 2024 Registration No.
April 10, 2024	LETTER	LETTER United States securities and exchange commission logo April 10, 2024 Kevin Danahy Chief Executive Officer Pulse Biosciences, Inc.
April 4, 2024	CORRESP	PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, California 94545 (510) 906-4600 April 4, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-278322 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securitie
April 3, 2024	EX-99.6	Form of Beneficial Owner Election Form EXHIBIT 99.6 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024] (THE “PROSPECTUS”), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. PULSE BIOSCIENCES, INC. BENEFICIAL OWNER ELECTION FORM I (We), t
April 3, 2024	EX-4.2	Form of Subscription Rights Certificate Exhibit 4.2 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024] (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. PULSE BIOSCIENCES, INC. Incorporated under the laws of the State o
April 3, 2024	EX-99.3	Form of Letter to Brokers and other Nominee Holders EXHIBIT 99.3 FORM OF LETTER TO BROKERS AND OTHER NOMINEE HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. [ [●], 2024] To Securities Dealers, Commercial Banks, Trust Companies, and Other Nominees: This letter is being distributed to securities dealers, commercial banks, trust companies, and other nominees in connec
April 3, 2024	EX-4.4	Warrant Agency Agreement, dated April 3, 2024 EXHIBIT 4.4 WARRANT AGENCY AGREEMENT WARRANT AGENCY AGREEMENT made as of April 3, 2024, between Pulse Biosciences, Inc., a Delaware corporation (“Company”), with offices at 3957 Point Eden Way, Hayward, California 94545, and Broadridge Corporate Issuer Solutions, LLC (“Warrant Agent”), with offices at 51 Mercedes Way, Edgewood, NY 11717 (the “Warrant Agreement”). WHEREAS, the Company is engaged in
April 3, 2024	S-3	As filed with the Securities and Exchange Commission on April 3, 2024 As filed with the Securities and Exchange Commission on April 3, 2024 Registration No.
April 3, 2024	EX-99.5	Form of Nominee Holder Certification EXHIBIT 99.5 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024 (THE “PROSPECTUS”) AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. PULSE BIOSCIENCES, INC. UNITS SUBSCRIBED FOR UPON EXERCISE OF SUBS
April 3, 2024	EX-99.2	Form of Letter to Stockholders who are Record Holders EXHIBIT 99.2 FORM OF LETTER TO STOCKHOLDERS WHO ARE RECORD HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. [ [●], 2024] Dear Stockholder: Enclosed are materials relating to a rights offering by Pulse Biosciences, Inc., a Delaware corporation (“we,” “us,” “our,” or the “Company”), including the prospectus dated [ [
April 3, 2024	EX-4.3	Form of Warrant Certificate EXHIBIT 4.3 PULSE BIOSCIENCES, INC. Warrant To Purchase Common Stock Warrant Shares: Initial Exercise Date: , 2024 THIS WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initia
April 3, 2024	EX-99.4	Form of Letter to Clients of Brokers and other Nominee Holders EXHIBIT 99.4 FORM OF LETTER TO CLIENTS OF BROKERS AND OTHER NOMINEE HOLDERS PULSE BIOSCIENCES, INC. Units Offered Pursuant to Subscription Rights Distributed to Stockholders of Pulse Biosciences, Inc. [ [●], 2024] To Our Clients: Enclosed for your consideration are the prospectus, dated [ [●], 2024] (the “Prospectus”), and the “Instructions as to Use of Pulse Biosciences, Inc. Non-Transferable Sub
April 3, 2024	LETTER	LETTER United States securities and exchange commission logo April 3, 2024 Kevin Danahy President and Chief Executive Officer Pulse Biosciences, Inc.
April 3, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc.
April 3, 2024	EX-99.1	Form of Instructions As To Use of Non-Transferable Subscription Rights Certificates EXHIBIT 99.1 THE TERMS AND CONDITIONS OF THE RIGHTS OFFERING ARE SET FORTH IN THE COMPANY’S PROSPECTUS DATED [ [●], 2024] (THE “PROSPECTUS”), AND ARE INCORPORATED HEREIN BY REFERENCE. COPIES OF THE PROSPECTUS ARE AVAILABLE UPON REQUEST FROM BROADRIDGE CORPORATE ISSUER SOLUTIONS, LLC, THE SUBSCRIPTION AGENT, BY CALLING (888) 789-8409. FORM OF INSTRUCTIONS AS TO USE OF PULSE BIOSCIENCES, INC. NON-TR
March 28, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 28, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
March 28, 2024	EX-10.27	Fourth Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated March 2024 Exhibit 10.27 PULSE BIOSCIENCES, INC. FOURTH AMENDMENT TO EMPLOYMENT AGREEMENT This fourth amendment (this “Amendment”) is entered into effective as of March 26, 2024, by and between Darrin Uecker (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Company and Executive entered into an employment agreement dated September 8, 2015 (as
March 28, 2024	EX-99.2	Pulse Biosciences Announces Plans to Initiate a Rights Offering Exhibit 99.2 Pulse Biosciences Announces Plans to Initiate a Rights Offering HAYWARD, Calif. [Business Wire] – March 28, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that its Board of Directors has unanimously approved plans to initiate a rights offering. The rights offeri
March 28, 2024	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Jurisdiction of Incorporation Ownership Position NanoBlate Corp., a Delaware Corporation Delaware 100% BioElectroMed Corp., a California Corporation California 100% Pulse Biosciences BV Netherlands 100% 2783162 Ontario Inc. Ontario 100%
March 28, 2024	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc.
March 28, 2024	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results HAYWARD, Calif. [Business Wire] – March 28, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full yea
March 28, 2024	EX-97.1	Section 10D Clawback Policy Exhibit 97.1 Incentive-Based Compensation Clawback Policy Effective November 2023 Pulse Biosciences, Inc. (“Company”) has adopted this clawback policy (the “Policy”) as a supplement to any other clawback policies in effect now or in the future at the Company. To the extent this Policy applies to compensation payable to a covered person, it shall be the only clawback policy applicable to such compe
March 28, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUA Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-348
March 28, 2024	S-3	As filed with the Securities and Exchange Commission on March 28,2023 As filed with the Securities and Exchange Commission on March 28,2023 Registration No.
March 28, 2024	EX-10.26	Third Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated March 2024 Exhibit 10.26 PULSE BIOSCIENCES, INC. THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This third amendment (this “Amendment”) is entered into effective as of March 26, 2024, by and between Kevin Danahy (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Parties entered into an employment agreement dated February 9, 2022 (as previously amended
March 28, 2024	EX-4.2	Form of Indenture Exhibit 4.2 PULSE BIOSCIENCES, INC. INDENTURE Dated as of , 20 [], As Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 6 1.1 Definitions 6 1.2 Other Definitions 8 1.3 Incorporation by Reference of Trust Indenture Act 8 1.4 Rules of Construction 9 ARTICLE II THE SECURITIES 9 2.1 Issuable in Series 9 2.2 Establishment of Terms of Series of Securities 9 2.3 Executio
March 11, 2024	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 8, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
March 11, 2024	EX-99.1	Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX Exhibit 99.1 Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System HAYWARD, Calif. [Business Wire] – March 8, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced receipt of U.S. Food and Drug Administration (FDA) 510(k) clearance for
February 14, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): February 14, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
February 14, 2024	EX-99.1	Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX Exhibit 99.1 Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study HAYWARD, Calif. [Business Wire] – February 14, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company with a primary focus on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) tec
January 9, 2024	EX-99.1	Investor Deck, dated January 2024 Exhibit 99.1
January 9, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 9, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
January 2, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 2, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): January 2, 2024 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
January 2, 2024	EX-99.1	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX Exhibit 99.1 Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp HAYWARD, Calif. [Business Wire] – January 02, 2024. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a p
December 22, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
December 20, 2023	EX-99.1	Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX Exhibit 99.1 Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif. [Business Wire] – December 20, 2023. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily
December 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 20, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
December 15, 2023	SC 13D/A	PLSE / Pulse Biosciences Inc / DUGGAN ROBERT W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 14)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI
December 4, 2023	SC 13D/A	PLSE / Pulse Biosciences Inc / DUGGAN ROBERT W - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 13)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI
December 4, 2023	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 tm2332044d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Pulse Bio
November 27, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 27, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
November 27, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)
November 21, 2023	EX-99.1	Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode Exhibit 99.1 Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode HAYWARD, Calif. [Business Wire] – November 21, 2023. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filin
November 21, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 21, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 21, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
November 13, 2023	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results Pulse Biosciences will host Third Quarter 2023 Financial Results conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023 HAYWARD, Calif. [Business Wire] – November 13, 2023. Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Cell
November 13, 2023	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒Preliminary Proxy Statement ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2
November 13, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 13, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commissi
November 13, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Numbe
September 12, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 10, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 10, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commiss
August 29, 2023	CORRESP	PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, CA 94545 (510) 906-4600 PULSE BIOSCIENCES, INC. 3957 Point Eden Way Hayward, CA 94545 (510) 906-4600 August 29, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Pulse Biosciences, Inc. Registration Statement on Form S-3 File No. 333-273944 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act
August 18, 2023	LETTER	LETTER United States securities and exchange commission logo August 18, 2023 Kevin Danahy Chief Executive Officer Pulse Biosciences, Inc.
August 11, 2023	S-3	As filed with the Securities and Exchange Commission on August 11,2023 As filed with the Securities and Exchange Commission on August 11,2023 Registration No.
August 11, 2023	EX-FILING FEES	Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Pulse Biosciences, Inc.
August 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 10, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission
August 10, 2023	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results HAYWARD, Calif. [Business Wire] – August 10, 2023 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced financial results for the second
August 10, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 00
July 20, 2023	EX-99.1	Investor Deck, dated July 20, 2023 Exhibit 99.1
July 20, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 20, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): July 20, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission F
May 31, 2023	EX-1.01	2022 Conflict Minerals Report of Pulse Biosciences, Inc. as required by Items 1.01 and 1.02 of this Form SD. Exhibit 1.01 Conflict Minerals Report of Pulse Biosciences, Inc. in Accordance with Rule 13p-1 under the Securities Exchange Act of 1934 This is the Conflict Minerals Report (“CMR”) of Pulse Biosciences, Inc. (“Pulse Biosciences” or the “Company”) for the reporting period January 1, 2022 to December 31, 2022 in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934,
May 31, 2023	SD	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM SD Specialized Disclosure Report Pulse Biosciences, Inc.
May 30, 2023	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 25, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi
May 11, 2023	SC 13D/A	PLSE / Pulse Biosciences Inc / DUGGAN ROBERT W - AMENDMENT TO FORM SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 12)1 Pulse Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 74587B 10 1 (CUSIP Number) ADAM W. FI
May 11, 2023	EX-99.1	PULSE BIOSCIENCES, INC. Condensed Consolidated Balance Sheets (In thousands, except per share amounts) Exhibit 99.1 Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results HAYWARD, Calif. [Business Wire] – May 11, 2023 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced financial results for the first quarter ended March 31,
May 11, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 11, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi
May 11, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 0
May 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 10, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fi
May 10, 2023	S-8	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under The Securities Act of 1933 Pulse Biosciences, Inc. (Exact name of Registrant as specified in its charter) Delaware 46-5696597 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification Number) 3957 Point Eden Way Hayward, Californ
May 10, 2023	EX-99.1	PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS Exhibit 99.1 PULSE BIOSCIENCES, INC. ANNOUNCES PLANNED REDEMPTION OF WARRANTS HAYWARD, Calif.-(BUSINESS WIRE)—May 10, 2023—Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for the treatment of atrial fibrillation, today announced that it intends to deliver an irrevocable notice of redemption, on or about May
May 10, 2023	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Pulse Biosciences, Inc. S-8 Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equ
May 9, 2023	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 5, 2023	EX-10.2	Amendment to Employment Agreement, between Darrin Uecker and Pulse Biosciences, Inc., dated May 5, 2023 EX-10.2 3 ex514883.htm AMENDMENT TO EMPLOYMENT AGREEMENT, BETWEEN DARRIN UECKER AND PULSE BIOSCIENCES, INC., DATED MAY 5, 2023. Exhibit 10.2 PULSE BIOSCIENCES, INC. THIRD AMENDMENT TO EMPLOYMENT AGREEMENT This third amendment (this “Amendment”) is entered into effective as of April 29, 2023 by and between Darrin Uecker (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Exe
May 5, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 4, 2023 Pulse Biosciences, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 001-37744 46-5696597 (State or Other Jurisdiction of Incorporation) (Commission Fil
May 5, 2023	EX-10.1	Amendment to Employment Agreement, between Kevin Danahy and Pulse Biosciences, Inc., dated May 4, 2023 Exhibit 10.1 PULSE BIOSCIENCES, INC. SECOND AMENDMENT TO EMPLOYMENT AGREEMENT This second amendment (this “Amendment”) is entered into effective as of April 29, 2023 (the “Amendment Date”) by and between Kevin Danahy (“Executive”) and Pulse Biosciences, Inc. (the “Company,” and together with Executive, the “Parties”). WHEREAS, the Parties entered into an employment agreement dated February 9, 2022
May 1, 2023	EX-99.1	PULSE BIOSCIENCES ANNOUNCES $65 MILLION PRIVATE PLACEMENT Exhibit 99.1 PULSE BIOSCIENCES ANNOUNCES $65 MILLION PRIVATE PLACEMENT HAYWARD, Calif. [Business Wire] – May 1, 2023 – Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology and proprietary CellFX System® for the treatment of atrial fibrillation, today announced that it has entered into a stock purchase agreement

PLSE / Pulse Biosciences, Inc. - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings